Biomaterial Database

Recurrences during the chemoprophylactic treatment of superficial tumors of the bladder. 1986

V Ferraris, and E Repetto, and P F Pisano, and D Albano

A total of 88 patients who underwent resection for superficial stages Ta and T1 bladder tumors received chemoprophylactic treatment to prevent recurrence postoperatively. The first 44 patients were given doxorubicin at monthly intervals and the second 44 received doxorubicin plus mitomycin C alternately, with the first 6 instillations at weekly intervals and the rest monthly beginning 1 month after resection. Recurrences during treatment were assessed as an index of drug resistance. Tumor developed while the patients were undergoing treatment (9 to 10 months) in 15.9 per cent (7 of 44) of group 1 patients, 18.1 per cent (8 of 44) of group 2 patients and 17.0 per cent (15 of 88) of the total patients studied. At the initial post-treatment cystoscopy 12 to 16 months later 2 more patients in group 1 and none in group 2 had recognizable tumors. Treatment was continued in patients with recurrences. A total of 41 recurrences in 435 months of followup was recorded, for a rate of 9.42 recurrences per 100 patient-months. No worsening of the histological grading was noted but 2 patients with initial stage T1 disease had subsequent carcinoma in situ.

UI	MeSH Term	Description	Entries
D008297	Male		Males
D008875	Middle Aged	An adult aged 45 - 64 years.	Middle Age
D008937	Mitomycins	A group of methylazirinopyrroloindolediones obtained from certain Streptomyces strains. They are very toxic antibiotics used as ANTINEOPLASTIC AGENTS in some solid tumors. PORFIROMYCIN and MITOMYCIN are the most useful members of the group.
D009364	Neoplasm Recurrence, Local	The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.	Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D001749	Urinary Bladder Neoplasms	Tumors or cancer of the URINARY BLADDER.	Bladder Cancer,Bladder Neoplasms,Cancer of Bladder,Bladder Tumors,Cancer of the Bladder,Malignant Tumor of Urinary Bladder,Neoplasms, Bladder,Urinary Bladder Cancer,Bladder Cancers,Bladder Neoplasm,Bladder Tumor,Cancer, Bladder,Cancer, Urinary Bladder,Neoplasm, Bladder,Neoplasm, Urinary Bladder,Tumor, Bladder,Tumors, Bladder,Urinary Bladder Neoplasm
D002291	Carcinoma, Papillary	A malignant neoplasm characterized by the formation of numerous, irregular, finger-like projections of fibrous stroma that is covered with a surface layer of neoplastic epithelial cells. (Stedman, 25th ed)	Carcinomas, Papillary,Papillary Carcinoma,Papillary Carcinomas
D004317	Doxorubicin	Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.	Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D005260	Female		Females
D005500	Follow-Up Studies	Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.	Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man